Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Matthew Denholtz"'
Autor:
Alexandra Bortnick, Zhaoren He, Megan Aubrey, Vivek Chandra, Matthew Denholtz, Kenian Chen, Yin C. Lin, Cornelis Murre
Publikováno v:
Cell Reports, Vol 31, Iss 13, Pp 107876- (2020)
Externí odkaz:
https://doaj.org/article/444ebdd2c37044669fba9ea15b9680d3
Autor:
John Goulding, Wen-I Yeh, Bryan Hancock, Robert Blum, Tianhao Xu, Bi-Huei Yang, Chia-Wei Chang, Brian Groff, Earl Avramis, Mochtar Pribadi, Yijia Pan, Hui-Yi Chu, Shohreh Sikaroodi, Lauren Fong, Nicholas Brookhouser, Thomas Dailey, Miguel Meza, Matthew Denholtz, Evelyn Diaz, Judy Martin, Peter Szabo, Sarah Cooley, Lucas Ferrari de Andrade, Tom T. Lee, Ryan Bjordahl, Kai W. Wucherpfennig, Bahram Valamehr
Publikováno v:
Med.
Autor:
Soheila Shirinbak, Joy Grant, Angela Gentile, Bishwas Shrestha, Philip Chu, Amit Mehta, Yijia Pan, Bjoern Gaertner, Mochtar Pribadi, Joyee Yao, Matthew Denholtz, Alec Witty, Layton Smith, Tom Lee, Eigen Peralta, Martin Hosking, Bob Valamehr
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Eigen Peralta, Dan Lu, Mark Landon, Hui-yi Chu, Soo Park, Masanao Tsuda, Trevor Zarecki, Elena Demeester, Matthew Denholtz, Amit Mehta, Earl Avramis, Philip Chu, Jeffrey Chen, Eric Sung, Alec Witty, Tom Lee, Bahram Valamehr
Publikováno v:
Blood. 140:7429-7430
Autor:
Cornelis Murre, Victor Nizet, Yi-Na Zhu, Hanbin Lu, Zhaoren He, Takeshi Isoda, Matthew Denholtz, Simon Döhrmann
Publikováno v:
Genes Dev
Differentiating neutrophils undergo large-scale changes in nuclear morphology. How such alterations in structure are established and modulated upon exposure to microbial agents is largely unknown. Here, we found that prior to encounter with bacteria,
Publikováno v:
Genes Dev
During developmental progression the genomes of immune cells undergo large-scale changes in chromatin folding. However, insights into signaling pathways and epigenetic control of nuclear architecture remain rudimentary. Here, we found that in activat
Autor:
Ryan Bjordahl, Michelle L. Saetersmoen, Lise Kveberg, Thomas H. Lee, Brian Groff, Jode P Goodridge, Bahram Valamehr, Camille Philippon, Karl-Johan Malmberg, Marianna Vincenti, Svetlana Gaidarova, Dan S. Kaufman, Sajid Mahmood, Frank Cichocki, Artur Cieslar-Pobuda, Hanna Julie Hoel, Matthew Denholtz, Minoru Kanaya, Quirin Hammer, Merete Thune Wiiger, Jeffrey S. Miller, Hui-yi Chu
Publikováno v:
Blood. 136:34-35
Induced pluripotent stem cell (iPSC)-derived natural killer (iNK) cells offer a promising platform for off-the-shelf immunotherapy against cancer. A unique benefit of iPSC-derived immune effector cells is the possibility to perform multiple precision
Differentiating neutrophils undergo large-scale changes in nuclear morphology. How such alterations in structure are established and modulated upon exposure to microbial agents is largely unknown. Here, we found that prior to encounter with bacteria,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0dba9a97236fafe0664518260517e81
https://doi.org/10.1101/808568
https://doi.org/10.1101/808568
Autor:
Joyee Yao, Thomas H. Lee, Dan Lu, Sandeep Kothapally Hanok, Daniel Shoemaker, Jason ORourke, Yinghui Sui, Natalie Navarrete, Matthew Denholtz, Bahram Valamehr, David J. Robbins, Eigen Peralta, Angela Gentile, Emily Carron, Cokey Nguyen, Eric Sung
Publikováno v:
Blood. 136:12-12
Despite the success of chimeric antigen receptor (CAR)-T cell therapy in various hematologic malignancies, obstacles to an effective therapeutic outcome are highly dependent on the tumor type being targeted and the immune microenvironment that the CA
Autor:
Bahram Valamehr, Samuel LaBarge, Yi-Shin Lai, Mochtar Pribadi, Suzanna Gasparian, Mandal Mili, Alma Gutierrez, Matthew Denholtz, Gloria Hsia, Jason ORourke, May Sumi, Bi-Huei Yang, Cokey Nguyen, Sandeep Kothapally Hanok, Alec Witty, Eric Sung, Amit R. Mehta, Raedun Clarke, Ramzey Abujarour, Eigen Peralta, Emily Carron, Thomas H. Lee, Emily Driver, Angela Gentile, Natalie Navarrete, David J. Robbins, Wen-I Yeh, Philip Chu, Chia-Wei Chang, Amanda D. Yzaguirre
Publikováno v:
Blood. 136:11-11
The development of chimeric antigen receptor (CAR) T cell therapeutics is widely recognized as a significant advancement for the treatment of cancer. However, several obstacles currently impede the broad use of CAR T cells, including the inherent pro